ATE435303T1 - Verfahren und zusammensetzungen in verbindung mit gen-silencing - Google Patents

Verfahren und zusammensetzungen in verbindung mit gen-silencing

Info

Publication number
ATE435303T1
ATE435303T1 AT03784781T AT03784781T ATE435303T1 AT E435303 T1 ATE435303 T1 AT E435303T1 AT 03784781 T AT03784781 T AT 03784781T AT 03784781 T AT03784781 T AT 03784781T AT E435303 T1 ATE435303 T1 AT E435303T1
Authority
AT
Austria
Prior art keywords
stranded rna
double
fragments
gene silencing
sequences
Prior art date
Application number
AT03784781T
Other languages
English (en)
Inventor
George Tzertzinis
George Feehery
Corinna Tuckey
Christopher Noren
Larry Mcreynolds
Original Assignee
New England Biolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Biolabs Inc filed Critical New England Biolabs Inc
Application granted granted Critical
Publication of ATE435303T1 publication Critical patent/ATE435303T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
    • C12Y301/26003—Ribonuclease III (3.1.26.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicon Polymers (AREA)
AT03784781T 2002-08-12 2003-07-18 Verfahren und zusammensetzungen in verbindung mit gen-silencing ATE435303T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40276902P 2002-08-12 2002-08-12
US40754302P 2002-08-30 2002-08-30
US46754103P 2003-05-02 2003-05-02
PCT/US2003/022540 WO2004015062A2 (en) 2002-08-12 2003-07-18 Methods and compositions relating to gene silencing

Publications (1)

Publication Number Publication Date
ATE435303T1 true ATE435303T1 (de) 2009-07-15

Family

ID=31721504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03784781T ATE435303T1 (de) 2002-08-12 2003-07-18 Verfahren und zusammensetzungen in verbindung mit gen-silencing

Country Status (8)

Country Link
US (2) US7700758B2 (de)
EP (1) EP1552018B1 (de)
JP (1) JP4339852B2 (de)
CN (1) CN1685063B (de)
AT (1) ATE435303T1 (de)
AU (1) AU2003256615A1 (de)
DE (1) DE60328214D1 (de)
WO (1) WO2004015062A2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3415625A1 (de) 2002-02-01 2018-12-19 Life Technologies Corporation Doppelsträngige oligonukleotide
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
CA2486658C (en) * 2002-05-31 2014-07-29 The Regents Of The University Of California Method for efficient rna interference in mammalian cells
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20050060771A1 (en) * 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
US20050059019A1 (en) * 2003-09-11 2005-03-17 Sven Bulow Gene-related RNAi transfection method
JP2007520221A (ja) 2004-01-23 2007-07-26 ニュー・イングランド・バイオラブズ・インコーポレイティッド 突然変異ｒｎａ分解酵素を用いた短い二重鎖ｒｎａの組成物および製造方法
WO2005095647A1 (ja) * 2004-03-31 2005-10-13 Takara Bio Inc. ｓｉＲＮＡのスクリーニング方法
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
WO2006000410A2 (en) * 2004-06-23 2006-01-05 Bayer Bioscience N.V. Method for identifying nucleic capable of modulating a gene in a biological system
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
ES2440953T3 (es) 2005-03-31 2014-01-31 The General Hospital Corporation Modulación de la actividad de HGF/HGFR para tratar un linfedema
ATE476986T1 (de) 2006-01-18 2010-08-15 Gen Hospital Corp Verfahren zur steigerung der lymphatischen funktion
BRPI0712607A8 (pt) 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
CA2676613A1 (en) * 2007-01-29 2008-08-07 Wyeth Immunophilin ligands and methods for modulating immunophilin and calcium channel activity
US20100113294A1 (en) 2007-04-16 2010-05-06 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
WO2009070465A1 (en) * 2007-11-29 2009-06-04 New England Biolabs, Inc. Selective purification of small rnas from mixtures
EP2297323A1 (de) 2008-05-21 2011-03-23 Hartmann, Gunther 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
US9447176B2 (en) 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
ES2704126T3 (es) 2011-08-23 2019-03-14 Found Medicine Inc Moléculas de fusión KIF5B-RET y usos de las mismas
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
MX381731B (es) 2012-05-14 2025-03-13 Biogen Ma Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
CA2880764C (en) 2012-08-03 2022-08-30 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
CN104870014A (zh) 2012-10-09 2015-08-26 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
EP2983804A4 (de) * 2013-03-15 2017-03-01 Moderna Therapeutics, Inc. Ionenaustauschreinigung von mrna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
EP2971161B1 (de) 2013-03-15 2018-12-26 ModernaTX, Inc. Nukleinsäurereinigung
EP2971033B8 (de) 2013-03-15 2019-07-10 ModernaTX, Inc. Herstellungsverfahren zur herstellung von rna-transkripten
EP3473272A1 (de) 2013-03-29 2019-04-24 Alexion Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur erhöhung der serumhalbwertzeit eines therapeutischen, gegen komplement c5 gerichteten mittels
HUE056760T2 (hu) 2013-07-11 2022-03-28 Modernatx Inc A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik
WO2015009831A2 (en) 2013-07-17 2015-01-22 Foundation Medicine, Inc. Methods of treating urothelial carcinomas
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CA2955238A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
US20180243370A1 (en) 2015-09-14 2018-08-30 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
SI3350333T1 (sl) 2015-09-17 2022-04-29 ModernaTX,Inc. Polinukleotidi, ki zajemajo stabilizacijsko repno regijo
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
CN109476731A (zh) 2016-02-29 2019-03-15 基础医药有限公司 治疗癌症的方法
CN109196121B (zh) 2016-02-29 2022-01-04 基因泰克公司 用于癌症的治疗和诊断方法
US12385034B2 (en) 2016-06-24 2025-08-12 Modernatx, Inc. Methods and apparatus for filtration
US20200031924A1 (en) 2016-07-13 2020-01-30 Biogen Ma Inc. Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders
WO2020002598A1 (en) 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
US20220056115A1 (en) 2018-09-17 2022-02-24 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
CN111073885A (zh) * 2019-12-31 2020-04-28 江苏耀海生物制药有限公司 一种应用于双链dna片段的纯化方法
CN112626152A (zh) * 2020-12-18 2021-04-09 深圳大学 siRNA的制备方法
CN113621686A (zh) * 2021-08-11 2021-11-09 海南微氪生物科技股份有限公司 一种适用于多种病原微生物的检测方法
WO2024045192A1 (en) * 2022-09-02 2024-03-07 Xiaomo Biotech Limited Inclusion body mediated method for double-stranded rna producing
WO2025049599A1 (en) 2023-08-29 2025-03-06 President And Fellows Of Harvard College Methods for treating muscle-related disorders by modulating prolyl hydroxylase 3

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
BRPI9908967B1 (pt) 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
WO2000044914A1 (en) * 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1235842A4 (de) 1999-10-15 2003-04-23 Univ Massachusetts Gene des rns-interferenzweges als hilfsmittel der gezielten gentischen interferenz
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
JP2003527856A (ja) 2000-03-17 2003-09-24 ベニテック オーストラリア リミテッド 遺伝子のサイレンシング
ATE450621T2 (de) * 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
US20020173478A1 (en) * 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
AU2002258477A1 (en) * 2001-03-08 2002-09-24 Advanced Cell Technology, Inc. Use of rna interference for the creation of lineage specific es and other undifferentiated cells and production of differentiated cells in vitro by co-culture
US7101995B2 (en) * 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
CA2486658C (en) * 2002-05-31 2014-07-29 The Regents Of The University Of California Method for efficient rna interference in mammalian cells

Also Published As

Publication number Publication date
AU2003256615A1 (en) 2004-02-25
US7700758B2 (en) 2010-04-20
JP2005535356A (ja) 2005-11-24
WO2004015062A2 (en) 2004-02-19
CN1685063B (zh) 2011-12-21
CN1685063A (zh) 2005-10-19
EP1552018A4 (de) 2007-11-21
US20080206835A1 (en) 2008-08-28
DE60328214D1 (de) 2009-08-13
JP4339852B2 (ja) 2009-10-07
WO2004015062A3 (en) 2005-02-24
EP1552018B1 (de) 2009-07-01
EP1552018A2 (de) 2005-07-13
AU2003256615A8 (en) 2004-02-25
US20040038278A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
DE60328214D1 (de) Verfahren und zusammensetzungen in verbindung mit gen-silencing
Van Dijk et al. Library preparation methods for next-generation sequencing: tone down the bias
WO2004046320A3 (en) METHODS AND COMPOSITIONS FOR REDUCING TARGET GENE EXPRESSION USING COCKTAILS OF siRNAS OR CONSTRUCTS EXPRESSING siRNAS
ATE469983T1 (de) Rolling-circle rna-amplifikation
Li et al. Identification and characterization of microRNAs in the spleen of common carp immune organ
ATE542918T1 (de) Verfahren zur quantifizierung von mikro-rnas und kleinen interferenz-rnas
AU2003294440A8 (en) Methods for using riboprimers for strand displacement replication of target sequences
MXPA05001355A (es) Formas nuevas adicionales de moleculas de arn de interferencia.
PL1687435T3 (pl) Odporność na owady z użyciem hamowania ekspresji genów
Zhang et al. MicroRNA profile analysis on duck feather follicle and skin with high-throughput sequencing technology
DE60331321D1 (de) Verfahren zur wirksamen rna-interferenz in säugerzellen
AR039717A1 (es) Construcciones de arn de intrones cadena doble y usos de las mismas
DE602006017192D1 (de) Verfahren zur herstellung von oligonukleotiden
ATE328075T1 (de) Verfahren zur hemmung der expression eine zielgens
TNSN08252A1 (en) Sirna anti myosine va et depigmentation de la peau
WO2007044468A3 (en) Method to treat flavivirus infection with sirna
PE20212248A1 (es) Molecula oligomerica de acido nucleico y uso de esta
BR0309766A (pt) Promotores usp semente especìficos para expressar genes em vegetais
WO2005042705A3 (en) Short interfering rna and micro-rna compounds and methods of designing, making and using the same
Laganà et al. Identification of general and heart-specific miRNAs in sheep (Ovis aries)
DE602005022443D1 (de) Schnelle synthese von oligonukleotiden
MX2007004686A (es) Moleculas de arn de multidominio que comprenden al menos un aptamero para suministrar arn de doble hebra a organismos nocivos.
MXPA02003422A (es) Alteracion de la expresion de genes con adnss producido in vivo.
WO2004094616A3 (en) Silencing transcription by methylation
ATE420975T1 (de) Methode zur linearen nicht-selektiven amplifikation von nukleinsäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties